论文部分内容阅读
目的:探讨中药清肝化瘀口服液在肝细胞癌患者肝动脉化疗栓塞(TACE)术后辅助治疗的临床疗效。方法:随机选取我院2006年2月至2007年2月间住院原发性肝细胞癌患者60例,治疗组30例,于TACE术后给予清肝化瘀口服液治疗28 d,对照组30例单纯TACE治疗。治疗前及治疗后28 d取血进行甲胎蛋白(AFP)测定,观测和评价治疗后不良反应(消化道反应:恶心、呕吐、腹胀、纳差。全身反应:发热、黄疸和白细胞下降)、生活质量,检测病灶变化及肝外转移(CT和/或超声及胸片检查,随访观察肺、骨、脑及淋巴结的转移情况)。结果:治疗组AFP值下降显著,两组病例有统计学意义(P<0.05);治疗组瘤体客观疗效及临床症状缓解率均优于对照组(P<0.05);治疗组发生肝外转移6例(20%),对照组发生肝外转移14例(46.7%)。对照组天冬氨酸转氨酶(AST)较治疗前增高者17例(56.7%),治疗组5例(16.7%),(P<0.01)。术后对照组发生发热、黄疸、恶心、腹胀等不良反应24例(80%),治疗组14例(46.7%),治疗组明显少于对照组(P<0.01);治疗组生活质量改善优于对照组(P<0.05)。结论:清肝化瘀口服液联合介入治疗,在瘤体客观疗效、临床症状的缓解率、患者生活质量、降低血中AFP水平、减轻化疗毒副作用等方面明显优于对照组。
Objective: To investigate the clinical curative effect of Qinggan Huayu oral liquid adjuvant therapy after hepatic arterial chemoembolization (TACE) in patients with hepatocellular carcinoma. Methods: Sixty patients with HCC who were admitted to our hospital from February 2006 to February 2007 were randomly selected, and 30 patients in the treatment group were treated with Qinggan Huayu oral solution after TACE for 28 days. The control group 30 Cases of simple TACE treatment. Pretreatment and 28th day after treatment, blood was taken for determination of AFP, and adverse reactions (digestive tract reactions: nausea and vomiting, bloating and anorexia, systemic reactions: fever, jaundice and leukopenia) were observed and evaluated. Quality of life, changes in lesions, and extrahepatic metastases (CT and / or ultrasound and chest radiography were followed up for lung, bone, brain and lymph node metastases). Results: The AFP value of the treatment group decreased significantly (P <0.05). The objective curative effect and clinical symptom relief rate in the treatment group were better than those in the control group (P <0.05). The treatment group had extrahepatic metastasis 6 cases (20%), control group occurred in 14 cases (46.7%) of extrahepatic metastases. Aspartate aminotransferase (AST) in the control group increased 17 (56.7%) compared with that before treatment, and 5 cases (16.7%) in the treatment group (P <0.01). There were 24 cases (80%) of fever, jaundice, nausea, abdominal distension and other adverse reactions in the control group after operation, and 14 cases (46.7%) in the treatment group were significantly less than those in the control group (P <0.01) In the control group (P <0.05). Conclusion: Qingganghyuyou oral liquid combined with interventional therapy is superior to the control group in terms of objective curative effect, remission rate of clinical symptoms, quality of life of patients, lowering blood AFP level and alleviating the side effects of chemotherapy.